Joseph W Kim MD

Assistant Professor of Medicine (Medical Oncology)

Specialties & Subspecialties

Cancer Center, Yale: Prostate and Urologic Cancers Program

Early Drug Development Program

Medical Oncology

Education & Training

  • M.D., Wake Forest University School of Medicine (2007)
  • Resident, Emory University School of Medicine , Internal Medicine  (2007 - 2010)
  • Fellow, National Institutes of Health , National Cancer Institute and National Heart Lung and Blood Institute  (2010 - 2013)

Patient Care

Accepts New Patients? Yes | Patient Type: Adult | Accepts referrals from patients


Clinical Interests

Prostate cancer, bladder cancer, immunotherapy, early drug development


Board Certifications

  • Hematology, Internal Medicine, Board Eligible
  • Internal Medicine, Board Certified (2010)
  • Medical Oncology, Board Certified (2013)

Clinical Trials

Conditions Study Title
Breast Cancer (ER, PR, and HER2 negative), Colorectal Cancer, Endometrial Cancer, Gastric Adenocarcinoma, Glioblastoma Multiforme, Head/ Neck Squamous Cell Carcinoma, Melanoma, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Prostate Cancer, Brain and Nervous System, Breast - Female, Breast - Male, Colon, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Other Female Genital, Ovary, Prostate, Rectum, and Stomach A Phase I/IIa, First Time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency
Bladder, Breast - Female, Lung, Pancreas, and Stomach A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Prostate A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF SIPULEUCEL-T WITH CONCURRENT VERSUS SEQUENTIAL ADMINISTRATION OF ENZALUTAMIDE IN MEN WITH METASTATIC CASTRATE RESISTANT PROSTATE CANCER
Breast - Female, Colon, Lung, Melanoma, skin, Ovary, Rectum, and Stomach A Phase I, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications
Breast - Female, Colon, Esophagus, Kidney, Liver, Lung, Melanoma, skin, and Pancreas A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors

More Clinical Trials...

Edit Profile